Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Wall Street Loves FIGS. So Why Do Price Targets Predict a Pullback?Written by Jennifer Woods. Publication Date: 3/2/2026. After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has rallied to a price it hasn't seen in nearly four years. The stock has surged almost 260% over the past year, including a 58% jump in the last month alone. That rally has been powered by strong earnings and a wave of bullish analyst commentary. Yet despite the gains and positive sentiment, the consensus 12-month price target sits at just $12.25 — almost 30% below the current share price. That raises a key question: how much of this recovery is supported by fundamentals, and how much is momentum? A closer look at FIGS' recent results and the stock's price action offers some clues. Early investors in FIGS enjoyed a quick windfall after the company's May 2021 IPO, which priced at $22 per share and climbed to $50 within a month as pandemic-driven demand for medical apparel surged. As COVID-19 pressures eased, however, the stock reversed sharply and traded below $8 within a year. In the years that followed, FIGS mostly stayed range-bound in the single digits. After dipping below $4 in April 2025, the shares began another uptrend. Earnings Momentum Sparks Rally Following steady gains after positive Q1 and Q2 2025 earnings, the Q3 2025 results, released on Nov. 6, accelerated the rally. That report showed stronger-than-expected revenue growth, robust demand across its core business, and healthy margins despite tariff pressures. The company also issued an upbeat outlook, raising full-year guidance for net revenue and adjusted EBITDA margins. Wall Street reacted positively, sending the stock up more than 30% over the following week and prompting Zacks Research to upgrade FIGS to Strong Buy from Hold. What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO. Click here to get the details and I'll show you how to claim your stake… Key Points - FIGS stock is up nearly 260% over the last year
- Strong earnings have fueled the rally
- Stock is trading almost 30% above the average price target
- Special Report: [Sponsorship-Ad-6-Format3]
Momentum continued after the Q4 2025 earnings report released on Feb. 26. The quarter delivered a 33% jump in revenue and marked the company's best quarterly sales, topping $200 million. In its earnings call, management pointed to broad-based strength: an expanding active customer base, higher average order values, and robust demand for scrubwear — which accounted for more than three-quarters of net revenue and rose 35% year over year. International sales contributed as well, climbing 55%. For the full year, net revenue rose 14% to a record $630 million. Despite tariff-related pressure on gross margins, profitability held up: full-year adjusted EBITDA margin beat the company's target by more than 200 basis points. Earnings And Outlook Spark Analyst Support FIGS issued an optimistic outlook for the year ahead, citing continued demand supported in part by growth in healthcare jobs. The company plans to expand into new international markets, prioritize growth opportunities across its business lines, and continue its stock buyback program. For fiscal 2026, FIGS expects net revenue to grow 10% to 12%, with improved profitability targets. Analysts responded with a flurry of upgrades and positive notes after the earnings release. Barclays raised its rating to Strong Buy from Hold; KeyCorp moved to Overweight from Sector Weight and set a $17 price target; Goldman Sachs shifted to Hold from Strong Sell; BTIG reiterated its Buy rating with a $15 target; and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets FIGS' strong results have been the primary catalyst for the stock's rise to four-year highs. Shares began climbing ahead of the Q4 report and jumped nearly 14% in the session before the release. After the results, the rally intensified: the stock surged 24% on the first trading day following the report and added another 10% the following day. As of March 4, the stock was trading above $17, roughly 30% above the average 12-month price target of $12.25 based on 10 analyst reports. That level is more than double Morgan Stanley's $8 target issued in January and matches the highest target of $17 set by KeyCorp. The gap between bullish analyst commentary and relatively modest price targets suggests analysts acknowledge FIGS' improving fundamentals but remain cautious about valuation. At current levels, the shares trade at a price-to-earnings ratio near 90, implying that much of the company's expected growth may already be priced in. Investors applauding the turnaround face a choice: continue to ride the momentum or brace for a possible pullback if results or sentiment falter.
| 
